JP2023501146A - 多重特異性抗体 - Google Patents

多重特異性抗体 Download PDF

Info

Publication number
JP2023501146A
JP2023501146A JP2022524675A JP2022524675A JP2023501146A JP 2023501146 A JP2023501146 A JP 2023501146A JP 2022524675 A JP2022524675 A JP 2022524675A JP 2022524675 A JP2022524675 A JP 2022524675A JP 2023501146 A JP2023501146 A JP 2023501146A
Authority
JP
Japan
Prior art keywords
cells
domain
scfv
her2
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524675A
Other languages
English (en)
Japanese (ja)
Inventor
ウレッヒ ダービド
ヘス クリスティアン
シモナン アレクサンドル
バルムート シュテファン
Original Assignee
ヌマブ セラピューティクス アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌマブ セラピューティクス アクチェンゲゼルシャフト filed Critical ヌマブ セラピューティクス アクチェンゲゼルシャフト
Publication of JP2023501146A publication Critical patent/JP2023501146A/ja
Priority to JP2025012821A priority Critical patent/JP2025078629A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022524675A 2019-11-04 2020-11-04 多重特異性抗体 Pending JP2023501146A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025012821A JP2025078629A (ja) 2019-11-04 2025-01-29 多重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19206959.9 2019-11-04
EP19206959.9A EP3816185A1 (en) 2019-11-04 2019-11-04 Multispecific antibody directed against pd-l1 and a tumor-associated antigen
PCT/EP2020/080941 WO2021089609A1 (en) 2019-11-04 2020-11-04 Multispecific antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025012821A Division JP2025078629A (ja) 2019-11-04 2025-01-29 多重特異性抗体

Publications (1)

Publication Number Publication Date
JP2023501146A true JP2023501146A (ja) 2023-01-18

Family

ID=68426333

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022524675A Pending JP2023501146A (ja) 2019-11-04 2020-11-04 多重特異性抗体
JP2025012821A Pending JP2025078629A (ja) 2019-11-04 2025-01-29 多重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025012821A Pending JP2025078629A (ja) 2019-11-04 2025-01-29 多重特異性抗体

Country Status (9)

Country Link
US (1) US20220411536A1 (https=)
EP (2) EP3816185A1 (https=)
JP (2) JP2023501146A (https=)
KR (1) KR20220092949A (https=)
CN (1) CN114981306A (https=)
AU (1) AU2020379182A1 (https=)
CA (1) CA3159904A1 (https=)
IL (1) IL292727A (https=)
WO (1) WO2021089609A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634998B8 (en) * 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
WO2022136693A1 (en) 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
EP4341294A1 (en) * 2021-05-21 2024-03-27 BeiGene Switzerland GmbH Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
IL310217A (en) * 2021-07-23 2024-03-01 Akeso Biopharma Inc Pharmaceutical composition and use
CN117730103A (zh) * 2021-08-02 2024-03-19 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
TWI876227B (zh) * 2021-11-17 2025-03-11 大陸商南京再明醫藥有限公司 多特異性抗體及其藥物用途
KR20240133746A (ko) * 2022-01-09 2024-09-04 아이-맵 바이오파마 컴파니 리미티드 다중특이적 작제물 및 이의 용도
IL314169A (en) * 2022-01-26 2024-09-01 Zymeworks Bc Inc Trispecific immunomodulatory T cell engager proteins
CN118574857A (zh) * 2022-01-27 2024-08-30 岩唐生物科技(杭州)有限责任公司 靶向cd3的多特异性抗体及其应用
WO2024036207A2 (en) * 2022-08-11 2024-02-15 University Of Florida Research Foundation, Incorporated Rabbit monoclonal antibodies targeting multiple myeloma cell surface antigens
WO2024061297A1 (en) * 2022-09-22 2024-03-28 Shanghai Henlius Biotech , Inc. Anti-b7h3 antibodies, multispecific antibodies and methods of use
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
CN121398845A (zh) * 2023-07-14 2026-01-23 嘉和生物药业有限公司 抗pd-1/ctla-4/tigit三特异性抗体及其用途
AU2024317606A1 (en) * 2023-07-29 2026-02-26 Chimagen Biosciences, Ltd Modified type e multi-specific antibodies

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220988A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
WO2019072868A1 (en) * 2017-10-10 2019-04-18 Numab Therapeutics AG MULTISPECIFIC ANTIBODIES
WO2019166650A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
EP1240337B1 (en) 1999-12-24 2006-08-23 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
AU2002335930B2 (en) 2001-03-09 2005-07-28 Morphosys Ag Serum albumin binding moieties
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
KR20060095385A (ko) 2005-02-28 2006-08-31 엘지전자 주식회사 세탁기의 헹굼 행정 제어 방법
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011006915A2 (en) 2009-07-16 2011-01-20 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
WO2016011069A1 (en) * 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
KR20180096789A (ko) 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
CN109310766A (zh) * 2016-02-26 2019-02-05 伊蒙纽斯私人有限公司 多特异性分子
EP3445788B1 (en) 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
AR110348A1 (es) * 2016-12-07 2019-03-20 Agenus Inc Anticuerpos y métodos de su utilización
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
SG11201911527QA (en) * 2017-06-05 2020-01-30 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
CN120248120A (zh) * 2017-10-10 2025-07-04 努玛治疗有限公司 靶向pdl1的抗体及其使用方法
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN109942704B (zh) * 2019-04-12 2023-01-20 深圳普瑞金生物药业股份有限公司 Hsa单域抗体、核酸及试剂盒
KR20230018397A (ko) * 2020-05-29 2023-02-07 누맙 세러퓨틱스 아게 다중 특이적 항체
EP3988568A1 (en) * 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
IL303171A (en) * 2020-12-23 2023-07-01 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
JP2024504471A (ja) * 2021-02-02 2024-01-31 ヌマブ セラピューティックス アーゲー Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220988A1 (en) * 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
EP3470426A1 (en) * 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
WO2019072868A1 (en) * 2017-10-10 2019-04-18 Numab Therapeutics AG MULTISPECIFIC ANTIBODIES
WO2019166650A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins

Also Published As

Publication number Publication date
AU2020379182A1 (en) 2022-06-16
JP2025078629A (ja) 2025-05-20
US20220411536A1 (en) 2022-12-29
IL292727A (en) 2022-07-01
WO2021089609A1 (en) 2021-05-14
KR20220092949A (ko) 2022-07-04
CN114981306A (zh) 2022-08-30
EP3816185A1 (en) 2021-05-05
CA3159904A1 (en) 2021-05-14
EP4055045A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
US20220411536A1 (en) Multispecific antibody
JP7442443B2 (ja) 多重特異性抗体
US20230391882A1 (en) Combination treatment
EP3470426A1 (en) Multispecific antibody
US20240392003A1 (en) Multispecific antibodies having specificity for ror1 and cd3
EP3915580A1 (en) Multispecific antibody
CA3183565A1 (en) Binding protein having h2l2 and hcab structures
US20230203162A1 (en) Multispecific antibody
EP4574844A1 (en) Multispecific antibodies having specificity for cd47 and pdl1
IL325173A (en) New antibodies targeting CD3 and another target and their uses

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241029

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422